Journal article
Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
Asia-Pacific Journal of Clinical Oncology, Vol.15(S9), pp.161-162
2019
Abstract
Background: We aimed to assess the role of genomic HLA‐I/II heterozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non‐small lung cancer treated by PD1/L1 inhibitors...
Details
- Title
- Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
- Authors/Creators
- A. Abed (Author/Creator)A. Khattak (Author/Creator)M. Millward (Author/Creator)A. Chopra (Author/Creator)E. Gray (Author/Creator)
- Publication Details
- Asia-Pacific Journal of Clinical Oncology, Vol.15(S9), pp.161-162
- Publisher
- John Wiley and Sons
- Identifiers
- 991005541441507891
- Copyright
- © 2019 John Wiley & Sons Australia, Ltd.
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
- Additional Information
- Special Issue: COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, 12–14 November 2019, Adelaide Convention Centre, South Australia
Metrics
21 Record Views